BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced it will release its fourth quarter 2024 financial results on Monday, February 24, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, where management will discuss financial results and provide a corporate update. Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section of BioCryst's website.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre 2024 lunedì 24 febbraio 2025. L'azienda ospiterà una conference call e un webcast alle 8:30 ET dello stesso giorno, durante il quale il management discuterà dei risultati finanziari e fornirà un aggiornamento aziendale. Le parti interessate possono accedere alla chiamata in diretta componendo il numero 1-844-481-2942 (nazionale) o 1-412-317-1866 (internazionale). Un webcast in diretta e la registrazione saranno disponibili nella sezione investitori del sito web di BioCryst.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha anunciado que publicará sus resultados financieros del cuarto trimestre de 2024 el lunes 24 de febrero de 2025. La compañía llevará a cabo una conferencia telefónica y un webcast a las 8:30 a.m. ET el mismo día, donde la dirección discutirá los resultados financieros y proporcionará una actualización corporativa. Las partes interesadas pueden acceder a la llamada en vivo marcando el 1-844-481-2942 (nacional) o el 1-412-317-1866 (internacional). Un webcast en vivo y una repetición estarán disponibles en la sección de inversores del sitio web de BioCryst.
BioCryst Pharmaceuticals (Nasdaq: BCRX)는 2025년 2월 24일 월요일에 2024년 4분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 동일한 날 오전 8시 30분 ET에 콘퍼런스 콜과 웹캐스트를 진행할 예정이며, 이 자리에서 경영진이 재무 결과에 대해 논의하고 기업 업데이트를 제공할 것입니다. 관심 있는 당사자는 1-844-481-2942 (국내) 또는 1-412-317-1866 (국제)로 전화하여 라이브 전화를 이용할 수 있습니다. 실시간 웹캐스트와 재생은 BioCryst 웹사이트의 투자자 섹션에서 이용할 수 있습니다.
BioCryst Pharmaceuticals (Nasdaq: BCRX) a annoncé qu'il publiera ses résultats financiers du quatrième trimestre 2024 le lundi 24 février 2025. L'entreprise organisera une conférence téléphonique et un webcast à 8h30 ET le même jour, au cours de laquelle la direction discutera des résultats financiers et fournira une mise à jour sur l'entreprise. Les parties intéressées peuvent accéder à l'appel en direct en composant le 1-844-481-2942 (national) ou le 1-412-317-1866 (international). Un webcast en direct et une rediffusion seront disponibles dans la section investisseurs du site Web de BioCryst.
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat bekannt gegeben, dass das Unternehmen am Montag, den 24. Februar 2025, seine Finanzergebnisse für das vierte Quartal 2024 veröffentlichen wird. Am selben Tag wird um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden, in dem das Management die Finanzergebnisse besprechen und ein Unternehmensupdate geben wird. Interessierte Parteien können die Live-Übertragung unter der Nummer 1-844-481-2942 (inländisch) oder 1-412-317-1866 (international) erreichen. Ein Live-Webcast und eine Wiederholung sind im Investorenbereich der Website von BioCryst verfügbar.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
When will BioCryst (BCRX) report Q4 2024 earnings?
What time is BioCryst's (BCRX) Q4 2024 earnings call?
How can investors access BioCryst's (BCRX) Q4 2024 earnings call?
Where can I find the replay of BioCryst's (BCRX) Q4 2024 earnings call?
